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Abstract The need to manage the key symptoms of chronic obstructive pulmonary disease (COPD) (breathlessness, 
cough and sputum) is an important treatment objective. Viozan TM (sibenadet HCI, AR-C68397AA) is a novel dual 
D 2 dopamine receptor, ~2-adrenoceptor agonist, which combines conventional bronchodilatory activity with the sensory 
nerve modulation afforded by dopamine agonism. The efficacy of this agent in relieving patient symptoms has been 
determined in a series of large-scale clinical studies; the results of a 3-month, placebo-controlled multi-centre study are 
reported. Effect on patient symptoms was determined using a novel patient-reported assessment instrument, the 
Breathlessness, Cough and Sputum Scale (BCSS©). Patients with smoking-related COPD were required to complete a 
2-week baseline period before being randomized to one of three treatment groups; sibenadet (500 I~g three times daily) 
plus placebo (twice daily); salmeterol (50 I~g twice daily) plus placebo (three times daily); placebo (twice daily) plus a 
second placebo (three times daily). All treatments were delivered via pressurized metered dose inhaler (pMDI) for 
12 weeks. From enrolment, patients were required to complete daily diary cards to record symptoms of breathlessness, 
cough and sputum, medication use and adverse events.The primary outcome measure was the difference between the 
mean BCSS total score measured over the baseline period and the mean BCSS total score in the final 4weeks of the 
treatment period. Secondary measures included assessment of lung function, rescue medication use, exacerbations, health- 
related quality of life, opinion of efficacy and safety. Although an initial reduction in BCSS total score (indicating symptom 
improvement) was seen with sibenadet herapy, this effect was not maintained for the study duration. Salmeterol therapy, 
however, resulted in a sustained reduction in BCSS total score. No notable benefit over placebo was seen in lung function, 
exacerbations or health-related quality of life with either active treatment. While the results of this study failed to 
demonstrate sustained efficacy with sibenadet herapy, they do indicate the value of symptom assessment in the clinical 
evaluation of new drugs for the treatment of COPD. 
© 2003 Elsevier Science Ltd 
INTRODUCTION 
The significant healthcare burden of chronic obstructive 
pulmonary disease (COPD) and the need for greater 
attention to diagnosis, management and prevention has 
been highlighted by the formation of the Global Initiative 
for Obstructive Lung Disease (GOLD).This collaborative 
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group of international experts has defined COPD as a 
disease state characterized by airflow limitation that is 
not fully reversible (I).Their recommendations specify 
that a diagnosis of COPD should be made in any patient 
who exhibits the key symptoms of cough, sputum 
production or dyspnoea, with airway obstruction 
confirmed by spirometric measurement. Although 
smoking cessation and oxygen therapy clearly slows 
disease progression, no drug therapy has been shown to 
modify the disease; symptom control and attempts to 
improve lung function therefore remain principal 
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management objectives. Despite the limited reversibility 
of airway obstruction characteristic of COPD, broncho- 
dilator therapy can offer some relief and in the absence 
of alternative strategies, remains central to patient 
management. 
In an effort to achieve greater therapeutic effect and 
improve treatment choices, research activity has included 
investigation of novel agents with a mechanism of action 
other than bronchodilation. Viozan TM (sibenadet HCI, 
AR-C68397AA) was being developed as the first in a 
novel class of dual D zdopamine receptor, 132-adreno- 
ceptor agonists. Studies using animal models of COPD 
symptoms have investigated the role of dopamine 
agonism and have demonstrated sibenadet-mediated 
inhibition of capsaicin-induced cough, histamine-induced 
tachypnoea, and reflex-induced mucus secretion (2). 
As sibenadet was designed principally to relieve the 
symptoms of COPD, effective clinical assessment of this 
novel agent required an outcome measure that would 
adequately describe changes in key COPD symptoms in 
response to therapy. In the absence of any widely 
accepted tools to assess symptoms in patients with 
COPD, a novel instrument was developed, the Breath- 
lessness, Cough and Sputum Scale (BCSS©).This score 
has been used throughout the clinical evaluation of 
sibenadet and the reliability, reproducibility and validity of 
this approach has been described (3). An initial dose- 
ranging study of sibenadet utilizing the BCSS indicated 
interesting clinical potential that warranted further 
investigation (4).A subsequent series of large-scale clinical 
studies has now been completed (5,6). Reported here 
are the results of a 3-month, placebo-controlled study 
conducted to test the efficacy and safety of sibenadet 
relative to salmeterol (a long-acting 132-agonist ) in 
patients with COPD. As the study requirements 
excluded patients with reversible airways disease, 
132-agonist response was expected to be low. Salmeterol 
was therefore included as a comparator; any additional 
benefits seen with sibenadet herapy could therefore be 
attributed to the dopaminergic property of sibenadet. 
METHODS 
Patient population 
The study population included subjects from both genders 
ranging in age from 40 to 80 years, with a diagnosis of 
COPD (with symptoms for > 2years), current or ex- 
smokers with a smoking history of -> 15 pack-years, 
forced expiratory volume in one second/forced vital 
capacity (FEVJFVC) ratio < 65%, and FEV I 20%-70% of 
the predicted normal. In addition, patients were required 
to have FEV I reversibility to 400 pg salbutamol of < 15% 
or < 200 ml. 
Patients with concurrent respiratory disease other 
than COPD, an onset of COPD under the age of 35, need 
for regular nebulized therapy or domiciliary oxygen, or 
who had experienced a COPD exacerbation in the 
6weeks leading up to the trial were excluded. Other 
exclusion criteria included concurrent malignancy (or 
any history of lung malignancy), concurrent cardio- 
vascular disease, the presence of any other disease or 
abnormality of clinical significance and pregnancy. 
Patients who had ever participated in a study of 
sibenadet were also excluded, as were patients who had 
participated in any clinical trial in the previous 3 months. 
Study design 
This double-blind, double-dummy, placebo-controlled 
study was conducted at 189 centres in 15 countries. 
Patients meeting the entry requirements followed a 
2-week baseline assessment period during which they 
could continue using their regular COPD medication at 
a stable dose, with the exception of 132-adrenoceptor 
agonists, J3-blockers, anticholinergics, dopamine ago- 
nists, dopamine antagonists, antibiotics (for the treat- 
ment of respiratory tract infections), neuraminidase 
inhibitors, leukotriene antagonists, 5-1ipoxygenase 
inhibitors, monoamine oxidase inhibitors, tricyclic 
antidepressants, bupropion, regular domiciliary oxygen 
and antitussives. Subjects were supplied with 
salbutamol inhalers to be used as required as rescue 
medication. Starting in the baseline period, patients 
were required to complete daily diary cards to record 
symptoms of breathlessness, cough and sputum, study 
and rescue medication use, changes in concomitant 
medication and any adverse events that occurred. 
Symptoms were scored using the BCSS (3) and those 
recording a total score of ___ 2 for any 7 consecutive 
days during the baseline period were randomized to 
one of three treatment groups: sibenadet (500 ~g three 
times daily) plus placebo (twice daily); salmeterol 
(50/~g twice daily) plus placebo (three times daily); 
placebo (twice daily) plus a second placebo (three 
times daily). All treatments were delivered via 
pressurized metered-dose inhaler (pMDI). 
The dose of sibenadet used in this study was selected 
on the basis of previous dose-ranging studies for 
optimal efficacy and safety (4). A concealed randomi- 
zation system reduced the risk of selection bias, and 
the use of a blinded double-dummy design ensured that 
neither patient nor investigator could be influenced by 
knowledge of treatment. Randomization was per- 
formed using random permuted blocks and an uneven 
scheme where patients were randomized on a 2:2:1 
ratio to sibenadet, salmeterol and placebo was used to 
maximize the number of patients receiving active 
treatment whilst maintaining adequate placebo control 
within the study. Since the possibility of a bias caused 
by the order in which treatments were taken was 
thought to be small a 'self-randomization' procedure 
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was adopted and the order in which patients chose to 
take their medication was not recorded. 
Following randomization, patients returned for clinic 
visits at 2, 4, 8 and 12 weeks (end of treatment period). 
At the 12-week visit, patients were instructed to 
continue to follow study restrictions, using only rescue 
medication for a further 4-week follow-up period, 
which culminated in a final clinic visit. 
This study was performed in accordance with the 
principles stated in the Declaration of Helsinki and 
approved by ethics committees at each participating 
centre. All patients gave written informed consent. 
Changes in health-related quality of life 
(HRQL) 
HRQL was measured using the disease-specific St 
George's Respiratory Questionnaire (SGRQ) (8),and the 
generic EuroQoL-5D (EQ-5D) (9). Questionnaires were 
completed by patients at clinic visits at the beginning and 
end of the treatment period, and at the end of the 
follow-up period. Due to the lack of a validated 
questionnaire translation, 41 patients [3% of the modified 
intent to treat (mITT) population] could not report 
SGRQ data, and 272 patients (20% of the mITT 
population) could not report EQ-5D data. 
Symptom assessment 
Changes in key COPD symptoms were determined 
using the BCSS, which is described in detail by Leidy 
etal. (3).This novel patient-reported outcome measure 
has been used in a number of sibenadet studies (4,5). 
Briefly, the degree of breathlessness, cough and sputum 
was each scored by patients daily in diary cards on an 
ordinal scale of 0 to 4, where 0 denotes an absence of 
symptoms and 4 denotes severe symptoms. The BCSS 
total score therefore comprises the sum of these three 
item scores and ranges from 0-12. The difference 
between the mean BCSS total score measured over the 
baseline period and the mean BCSS total score in the 
final 4 weeks of the treatment period constituted the 
primary outcome measure in this study. For use in 
international studies, the BCSS was translated into 
20languages and linguistic validation subsequently 
performed (7). 
Patients' and investigators' opinion of 
efficacy 
Patients' opinions of treatment efficacy were recorded at 
all clinic visits after randomization. Investigators' opinions 
were recorded at the end of the treatment period only. 
Opinion of treatment was defined as 'highly effective', 
'moderately effective', 'mildly effective', 'not effective', or 
'made condition worse'. 
Safety 
Adverse events were recorded at all clinic visits after 
randomization. Other safety variables monitored were 
pulse and blood pressure, measured at all clinic visits 
up to the end of the treatment period, and 12-lead 
ECG, haematology, clinical chemistry and urine 
analysis, and physical examination, undertaken at the 
start of the baseline period and at the end of the 
treatment period. 
Lung function, use of rescue medication 
and exacerbations 
Lung function measurements (FEV I, FVC and SVC [slow 
vital capacity]) were taken at each clinic visit throughout 
the study prior to the patient taking their morning dose 
of study treatment where possible. The number of 
actuations of rescue medication was recorded daily in 
the diary cards. 
COPD exacerbations were defined as worsening 
symptoms of COPD requiring drug therapy in addition 
to study drug, rescue medication and doses of 
concomitant COPD medications. COPD exacerbations 
since the previous clinic visit were recorded at each visit 
after randomization. Investigators were asked to indicate 
whether each adverse event a patient experienced was 
consistent with the definition of a COPD exacerbation. 
Both adverse events that had been flagged by the 
investigator as an exacerbation and adverse events that 
were described as an 'exacerbation' were included in the 
analysis (extended data). 
Statistical analyses 
Analyses were performed on the ITT population, 
defined as all randomized patients who received at least 
one dose of study drug with useable post-randomization 
efficacy data. A safety population was defined as all 
randomized patients receiving at least one dose of study 
medication and was used to summarize all safety data 
according to the treatment he patient received. 
The primary analyses examined the pairwise 
differences between treatment groups in their change in 
mean BCSS total scores from the baseline period to the 
final 4 weeks of the treatment period. These compari- 
sons were made using analysis of covariance 
(ANCOVA) with treatment and country as fixed 
factors and the mean BCSS total score over the 
baseline period as a covariate. In order to maintain the 
overall significance level of 5% for these confirmatory 
analyses of the primary endpoint, the step-up 
sequential rejection procedure proposed by Hochberg 
was used (10). 
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Secondary analyses examined additional efficacy 
variables including the individual components of the 
BCSS, the spirometric variables, the SGRQ and EQ-5D 
scores and the patient and investigator opinion of 
efficacy. Continuous variables were examined using 
ANCOVA as for the primary endpoint, and categorical 
variables were examined using the chi-square test. Since 
the study was not prospectively powered to detect 
differences in these secondary variables, and the 
secondary analyses were deemed supportive or 
exploratory, no correction was made to the significance 
level. All statistical analyses were performed using SAS 
(Version 6-12). 
Based on data from a previous study (4), 890 patients 
were required to complete the study - 356 patients in 
the sibenadet and salmeterol groups and 178 in the 
placebo group.This would allow detection of a difference 
of at least 0-3 in the change from baseline to the final 
4 weeks of the treatment period, between the sibenadet 
and salmeterol groups, assuming a pooled standard 
deviation of 1.425, using a two-sided test at the 5% SL 
with 80% power. 
RESULTS 
Pat ient  demographics 
The patient disposition is illustrated in Figure I. Of the 
186 patients who discontinued the study prematurely, 
most withdrew due to disease deterioration, other 
adverse events, or withdrawal of consent. 
The baseline characteristics of patients randomized to 
treatment are summarized in Table I. Any differences 
noted between treatment groups at baseline were not 
considered clinically relevant. In total, 87% of patients 
were taking COPD medications before enrolment.The 
most frequently used COPD medications were selective 
short-acting inhaled [~z-agonists (55%), oral/inhaled 
steroids (54%), anticholinergics (33%), selective long- 
acting inhaled ~2-agonists (25%), and xanthines (22%). 
There were no notable differences between treatment 
groups. 
Compliance with study medication as recorded by the 
patients on their diary cards was high. The mean 
percentage compliance with study medication was over 
97% in all treatment groups. 
Changes in patient symptoms 
At the start of the treatment period there was an 
immediate reduction in mean BCSS total score 
(reflecting improvement in symptoms) in all three 
treatment groups.The change from baseline was greater 
in the sibenadet and salmeterol groups than in the 
placebo group. In the sibenadet group the reduction in 
mean BCSS total score (indicating symptom improve- 
ment) was maintained for approximately 6 weeks before 
increasing and staying at this level to the end of the 
treatment period (Figure 2).A similar early reduction in 
BCSS total score was observed in the salmeterol group 
and the decrease was maintained throughout the 
treatment period.The less marked, but notable, decrease 
in mean BCSS total score seen in the placebo group was 
maintained until weeks 5-6 before increasing and again 
decreasing at the end of the study period. At the end of 
the study period, none of the three treatment groups 
had returned to the levels recorded during the baseline 
period.The least squares (LS) mean differences between 
treatments for the change from baseline to the final 
4weeks of the treatment period (weeks 9-12) in the 
mean BCSS are shown in Table 2. 
A similar pattern of change to those observed for the 
BCSS total score were seen for the individual symptoms 
of breathlessness, cough and sputum, with decreases in 
symptoms at the start of the treatment period in the 
sibenadet and salmeterol treatment groups. Greater 
improvements were observed with sibenadet compared 
with placebo, and with salmeterol compared with both 
sibenadet and placebo. 
Lung function and rescue medicat ion  
use 
No notable changes in SVC, FVC or FEV I were seen over 
the course of the study. 
There was an immediate decrease in the number of 
actuations of rescue medication taken at the start of the 
treatment period in each treatment group, the decreases 
being maintained for the duration of the treatment 
period (Figure 3). No notable differences were seen 
between the sibenadet and salmeterol groups; the LS 
mean difference in the change from baseline to the final 
4 weeks of the treatment period between the sibenadet 
and placebo groups was -1"20 actuations (95% CI [-I.63, 
-0.76]). In the salmeterol group, the LS mean difference 
vs. placebo was-I "33 actuations (95% CI [-I-75,-0-90]). 
Exacerbations 
The proportion of patients experiencing at least one 
exacerbation over the course of the study was 21.4% and 
17. I% in the sibenadet and salmeterol groups respectively, 
compared with 21.9% of patients in the placebo group. 
No notable differences were seen within or between 
any treatment groups either in the number of patients 
experiencing an exacerbation or in the time to the first 
exacerbation (Figure 4). 
Health-related quality of l i fe 
In the SGRQ total score and also in the three domain 
scores (symptoms, activity and impacts), there was a 
greater improvement (reduction in score) from baseline 
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Patients enrolled 
n=1925 
Patients randomized 
n=- 1368 
Sibenadet 
n=-543 
Salmeterol 
n=554 
Placebo 
n=271 *
Completed 
n=464 
Completed 
n=493 
Completed 
n=224 
* 1 patient did not receive any study medication and was excluded from the I1-1" and safety populations 
FIGURE I. Flow chart of patient disposition. 
to the end of the treatment period in the salmeterol 
group when compared with both the sibenadet and the 
placebo treatment groups (Table 3). Patients receiving 
salmeterol therapy reported the greatest reductions in 
total and domain scores, those in the placebo group 
reported the least improvement. Large changes were 
observed in each of the three treatment groups for the 
symptom domain. 
Overall, the weighted health index (EQ-5D) showed 
no differences between the three treatment groups in 
the change from baseline to the end of the treatment 
period. 
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Opinion of efficacy 
Little change in the patients' opinion of efficacy was seen 
throughout the study and no notable differences were 
observed between the treatment groups (Figure 5). 
Patients were more likely to rate any treatment as being 
highly or moderately effective than the investigators. 
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Adverse  events  
The safety population consisted of 1367 patients. All 
received treatment according to randomization with the 
exception of three patients where errors were made in 
distributing the treatment hey were to receive between 
weeks8 and 12. One patient randomized to placebo 
received sibenadet, one patient randomized to 
salmeterol received placebo and one patient randomized 
to placebo received salmeterol. 
Adverse events reported in > 3% of patients in any 
treatment group are outlined in Table 4. Of the known 
adverse effects of ~2-adrenoreceptor agonists, dizziness 
and headache was reported by a similar percentage of 
patients in the sibenadet, salmeterol and placebo groups, 
although more patients in the sibenadet group reported 
tremor than those receiving salmeterol or placebo. 
Clinically significant abnormal laboratory values were 
noted for < 0-7% of patients within any treatment group. 
During the treatment period, severe adverse events 
were reported for 7, 6and I I% of the sibenadet, 
salmeterol and placebo patients respectively. Of these 
patients, II (2%) sibenadet patients, 13 (2%) salmeterol 
patients and 10 (4%) placebo patients had severe adverse 
events considered possibly or probably related to study 
drug, these were largely due to deterioration of disease 
during study (1% of all three treatment groups), 
palpitations (two sibenadet patients), dyspnoea (two 
salmeterol patients) and aggravated dyspnoea (one 
salmeterol and two placebo patients). 
One death was reported in the placebo group during 
the treatment period. Five patients died during the 
follow-up period: three in the sibenadet group, and one 
each in the salmeterol and placebo groups. 
DISCUSSION 
Symptoms and objective measures of airflow limitation 
have been identified as key indicators of need for 
treatment adjustment and impending complications (I). 
The extent to which symptom assessment can evaluate 
therapeutic benefits of treatment and differentiate 
between treatment approaches has not yet been 
established. The findings of this 3-month placebo- 
controlled study of the novel dual D 2 dopamine 
receptor, 132-adrenoceptor agonist sibenadet and a 
conventional bronchodilator, salmeterol, provide valuable 
insight in this area. 
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While no notable differences were seen between 
active treatment groups for any of the secondary 
analyses performed, the primary analysis, which 
described changes in BCSS total score, did illustrate 
statistically significant differences in treatment effect. 
Although the initial reduction in BCSS total score seen 
with sibenadet therapy was consistent with results 
observed in the short-term clinical studies (4), this effect 
was not sustained in this longer-term study confirming 
the tolerance seen in a concurrent large-scale study of 
sibenadet (5).The BCSS total score did, however, clearly 
reflect a reduction in the severity of symptoms 
associated with salmeterol treatment during the course 
of the 3-month trial relative to sibenadet and placebo. 
No disease modifying effects were expected, and this 
was confirmed by an absence of change in trough FEV I in 
any treatment group over the study period. Despite a 
lack of change in spirometric indices, opinion of 
treatment emcacy reported by patients and physicians 
suggest both active treatment groups perceived a 
therapeutic benefit. A considerable placebo effect was, 
however, also seen, which was also reflected in the 
SGRQ reporting. Interestingly, the magnitude of change 
in the placebo arm of this study approached the value of 
4 units that is deemed to represent a clinically significant 
change. However, this early positive response in the 
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placebo group to the enrolment in drug studies has been 
noted in previous reports (I I).This finding underscores 
the need to include a control group in any study of a new 
medication. 
Despite the absence of notable differences between 
treatment groups in conventional parameters such as 
spirometric indices and health-related quality of life, 
assessment of symptom severity using the BCSS was able 
to describe the beneficial effect of a long-acting 
132-agonist highlighting the potential application of this 
approach in monitoring and differentiating longitudinal 
therapeutic benefit. Considering the undoubted 
importance of the key symptoms of COPD, these data 
therefore could be considered indicative of the need for 
assessment approaches that determine changes in 
symptomatology in addition to lung function parameters. 
It could, however, be argued that as improvement in 
patient symptoms was not mirrored by improvement in 
secondary parameters such as quality of life or opinion 
of efficacy, the BCSS may be detecting changes too small 
to be of clinical relevance and have a detectable impact 
on the patients' condition. 
While a small difference in the proportion of patients 
experiencing at least one exacerbation was noted in 
patients receiving salmeterol (I 7% vs. approximately 2 I% 
in the sibenadet and placebo groups), no difference was 
seen in time to first exacerbation.The observed lack of 
difference between salmeterol and placebo in days to 
first exacerbation is in contrast with previous reports 
that show a delayed exacerbation onset with salmeterol 
therapy (12). These data suggest that maintenance 
treatment with long-acting ~2-agonists alone is not 
sufficient for controlling COPD exacerbations. 
In accordance with the other studies conducted as 
part of the large-scale clinical evaluation of sibenadet, the 
data reported here have shown no sustained clinical 
benefit associated with this novel agent (5). Despite a 
comprehensive body of animal model studies and 
positive early clinical indications, the contribution of 
D2agonism to relieving COPD symptoms remains 
unproven.The findings of this study could be considered 
to indicate the value of symptom assessment as a key 
outcome measure in clinical trials of patients with 
COPD. The lack of differentiation between treatment 
groups in terms of trough FEV I suggests that use of this 
objective indicator of disease severity alone could fail to 
detect important treatment-related benefits. In 
conclusion therefore, these data demonstrate that 
measures of symptom severity could offer important 
information concerning the therapeutic effect of 
treatment in COPD on relief of the core symptoms of 
breathlessness, cough, and sputum, worthy of further 
investigation. 
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